Maleki Majid, Vakilian Farveh, Amin Ahmad
Department of Cardiology, Rajai Cardiovascular, Medical and Research Center, Tehran University of Medical Science, Tehran, Iran.
Cardiology Department, Mashad University of Medical Science, Imam Reza Hospital, Mashad, Iran.
Heart Asia. 2011 Jan 1;3(1):143-9. doi: 10.1136/heartasia-2011-010023. eCollection 2011.
Heart failure (HF) is a growing public health concern as a consequence of the ageing of the population and the improved survival of patients with HF. HF is defined as impaired organ perfusion and/or high filling pressure. It is a systemic and chronic disease and as such involves many organs, not least the liver and kidney. The complex vascular system of the liver and its high metabolic activity render it vulnerable to circulation disturbances and trigger many molecular and haemodynamic changes in patients. There are many studies describing the impact of liver disease on patient outcomes. Hepatic dysfunction is commonly seen in HF patients and is closely correlated with a poor outcome. Knowledge about the mechanisms and impacts of liver disease in HF helps us to know the stage of the disease and treat it properly. Moreover, many drugs and toxins that are metabolised in the liver and contribute to drug interactions should also be taken into account when prescribing medication for HF patients. In light of the above-mentioned points, the authors have compiled this review on congestive hepatopathy with the aim of providing physicians and cardiologists with a succinct and useful guide on the role of the liver in HF.
由于人口老龄化以及心力衰竭(HF)患者生存率的提高,心力衰竭已成为一个日益严重的公共卫生问题。HF被定义为器官灌注受损和/或充盈压升高。它是一种全身性慢性疾病,涉及许多器官,尤其是肝脏和肾脏。肝脏复杂的血管系统及其高代谢活性使其易受循环紊乱影响,并在患者体内引发许多分子和血流动力学变化。有许多研究描述了肝脏疾病对患者预后的影响。肝功能障碍在HF患者中很常见,且与不良预后密切相关。了解肝脏疾病在HF中的机制和影响有助于我们了解疾病阶段并进行恰当治疗。此外,在为HF患者开处方时,还应考虑许多在肝脏中代谢并导致药物相互作用的药物和毒素。鉴于上述要点,作者编写了本关于充血性肝病的综述,旨在为内科医生和心脏病专家提供一份关于肝脏在HF中作用的简洁实用指南。